Lo.Li.Pharma s.r.l.
🇮🇹Italy
- Country
- 🇮🇹Italy
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.lolipharma.it/it
Clinical Trials
29
Active:0
Completed:22
Trial Phases
2 Phases
Phase 4:2
Not Applicable:25
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
Not Applicable
25 (92.6%)Phase 4
2 (7.4%)Specific Supplementation in Counteracting the Adverse Effects of Oral Contraceptives
Not Applicable
Withdrawn
- Conditions
- Contraception
- Interventions
- Drug: Oral contraceptiveDietary Supplement: Zyxelle
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Lo.Li.Pharma s.r.l
- Registration Number
- NCT07071389
- Locations
- 🇮🇹
Studio Medico Anteo, Terni, TR, Italy
Treatment of Menstrual Cycle Alterations in Adolescents
Not Applicable
Recruiting
- Conditions
- AmenorrheaOligomenorrheaPCOS (Polycystic Ovary Syndrome)
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Lo.Li.Pharma s.r.l
- Target Recruit Count
- 20
- Registration Number
- NCT06800170
- Locations
- 🇬🇪
Zhordania and Khomasuridze Institute of Reproductology, Tbilisi, Georgia
🇮🇹Agunco, Rome, Italy
🇷🇺Department of Obstetrics and Gynecology with Reproductive Medicine, F.I. Inozemtsev Academy of Medical Education, Saint Petersburg, Russian Federation
Treatment of Women With Hyperandrogenic PCOS With Two Different Ratios of Myo-inositol:D-chiro-inositol: A Comparison
Not Applicable
Completed
- Conditions
- Polycystic Ovarian Syndrome (PCOS)
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Lo.Li.Pharma s.r.l
- Target Recruit Count
- 30
- Registration Number
- NCT06715527
- Locations
- 🇮🇹
Alma Res Fertility Center, Rome, ITA, Italy
Treatment of Women With PCOS of Phenotype D
Not Applicable
Recruiting
- Conditions
- PCOS (Polycystic Ovary Syndrome)
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Lo.Li.Pharma s.r.l
- Target Recruit Count
- 20
- Registration Number
- NCT06639698
- Locations
- 🇮🇹
Alma Res Fertility Center, Rome, ITA, Italy
The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.
Not Applicable
Recruiting
- Conditions
- HPV Infection
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Lo.Li.Pharma s.r.l
- Target Recruit Count
- 100
- Registration Number
- NCT06285357
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found